Transasia sets up Asia's largest factory for coronavirus testing kits
Business Today I Mumbai I 9th June 2020: Mumbai-based Transasia Bio-Medicals, the largest domestic laboratory diagnostics maker, has set up a factory at Andhra Pradesh MedTech Zone in Visakhapatnam to manufacture various COVID-19 diagnostic kits. The unit is claimed to be the largest in Asia for its capacity. The Vizag factory, now ready and spread over 35,000 sq. ft of production space, is planning to make Elisa-based antibody detection test kits, RT-PCR (reverse transcription-polymerase chain reaction) kits, and rapid test kits within one month's time as final approvals from various Indian regulatory agencies are awaited, Suresh Vazirani, chairman, and managing director, Transasia Bio-Medicals said.
"This unit can make 10 lakh Elisa-based antibody detection test kits per day. The same facility will also make RT-PCR and rapid test kits and this will be the largest manufacturing facility in Asia for COVID-19 products," he said.
About five days ago, the Indian Council for Medical Research (ICMR) had sanctioned the import of Elisa test kits developed by the R&D team of Transasia's US subsidiary Calbiotech Group of Companies. The US Food and Drug Administration (FDA) and the European Union (EU) have already cleared the product and Transasia supplies the kits to the US, Italy, Spain, Brazil, and many countries in the developed world. Calbiotech makes about 10 lakh Elisa kits per day. Transasia is among a dozen suppliers of such kits to the US, which is currently testing its citizens with about 10 lakh Elisa tests per day. The kit was developed by Transasia within one and half months of research and had got the US approval within a week's time, said Vazirani.
"At present, we are looking at supplying about one lakh imported kits from the US and once domestic manufacturing begins, we can supply at half the price of RT-PCR kits, at less than Rs 1000," said Vazirani.
India is yet to start extensive use of Elisa testing. An indigenous Elisa test named "Covid Kavach Elisa" developed by the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV) at Pune has been transferred to Ahmadabad-based drugmaker Zydus Cadila for mass-scale production. A Biocon Group company Syngene and a couple of domestic manufacturers also have developed Elisa test kits using the ICMR technology, said sources.
Elisa stands for Enzyme-linked immunosorbent assay. Elisa test platforms have been used for many decades to detect infectious diseases like Hepatitis-B, Hepatitis-C, and HIV and the machines are available in most of the diagnostic labs. Elisa tests can detect antigens by measuring blood components like IgM and IgG. The test will determine whether the blood sample has developed antigens (in IgM) during the onset of disease and long-term immunity after a few days of infection with the IgG tests.
While real-time RT-PCR is the front-line test for clinical diagnosis of SARS-CoV-2, antibody tests are critical for surveillance to understand the proportion of the population exposed to infection. It will help find if 'herd immunity' is developing in a population. The advantage is it is easy to test large population in non-laboratory setups with faster turnaround time and at cheaper rates than RT-PCR tests. Another advantage is that it can test 100 samples in an hour compared to very few samples in RT-PCR. Further, it has an accuracy rate of 98 percent, whereas the RT-PCR accuracy rate is only 30-35 percent.
Vazrani established Rs 1,300-crore turnover Transasia Bio-Medicals in Mumbai in 1979. The firm focuses on laboratory diagnostics and equipment. In 2002, Transasia acquired Europe-based Erba Mannheim and its subsidiaries in the US, UK, and Germany and grouped them under the Transasia-Erba Group.
Read more: https://www.businesstoday.in/sectors/pharma/mumbai-firm-sets-up-asia-largest-factory-for-coronavirus-testing-kits/story/406443.html
About Transasia Bio-Medicals Ltd.:
Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics.
Transasia provides doctors and patients with reliable, affordable, and innovative Medical Diagnostic Systems, with an impressive install base of above 70,000 pieces of equipment across 30,000 labs in India. Over 150 crore blood tests get done every year on a Transasia instrument. Its team of sales and service support is the largest in the Indian IVD Industry. The vast network of more than 300 service engineers, 400+ Sales and Marketing Teams, 25 zonal offices, and 350+ Distributors allow us to reach out to over 5000 tier II-IV cities, towns, and villages including the farthest northeastern regions.
It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s. Today, Transasia’s indigenous research has resulted in the development of state-of-the-art, ‘Make in India’ products and technologies, enabling its products to be among the best in the world.
All along its journey spanning more than four decades, Transasia has been recognized for its commitment to healthcare. The Govt. of India has bestowed Transasia with the 'India Medical Devices Export Company of the Year’ award. Besides this, Transasia was conferred the ‘Economic Times- Best Brand 2019’ amongst many others.
Headquartered in Mumbai, Transasia is a part of the global Erba Group. The Erba –Transasia Group has spread its footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia, and Turkey through various acquisitions.
Erba’s production sites in India, Czech Republic, and USA and R&D centres in France, UK, India and Czech Republic form a hub for indigenous manufacturing of world-class deliverables. Today, the Erba -Transasia Group serves millions across 100 countries. For further information, kindly visit www.erbamannheim.com